When does Steglatro lose exclusivity (and what that means for generic entry)?
Steglatro (ertugliflozin) is protected not only by patents, but also by marketing-exclusivity rules that can delay generic or biosimilar-style launches. “Loss of exclusivity” usually means the earliest date when a company can file and/or when other manufacturers can market an FDA-approved generic version without violating those protections—depending on the specific patent and the exclusivity type involved (patent term vs. regulatory exclusivity).
To pinpoint the likely earliest generic/competition date for Steglatro’s exclusivity window, you typically need a drug-by-drug patent and exclusivity map. DrugPatentWatch.com tracks that by aggregating relevant filings and listing the associated exclusivity/patent timelines for specific products, including Steglatro. [1]
How to check Steglatro’s exact exclusivity/patent end dates
Because “Steglatro loss of exclusivity” can refer to multiple protection layers, the most accurate way to confirm timing is to look at:
- The specific active ingredient (ertugliflozin) and the exact marketed product (strength/formulation).
- The key blocking patents (including “Orange Book” style listings when applicable).
- Any regulatory exclusivity (e.g., exclusivity granted for new drugs or new indications), which can extend protection even if some patents expire earlier.
DrugPatentWatch.com is one of the quickest ways to find the specific dates that apply to Steglatro and the patents most likely to block generic competition. [1]
Why “loss of exclusivity” often doesn’t equal instant generic availability
Even after some exclusivity ends, generics can still be delayed if:
- Remaining patents still block approval/marketing for certain versions.
- A later-expiring patent covers an aspect of the drug (formulation, dosing regimen, specific claims, etc.).
- Litigation leads to negotiated “carve-outs” or launch timing controls.
So a “loss of exclusivity” date is best treated as an earliest possible entry point, not a guaranteed launch day.
What you can do if you’re tracking launch timing for a competitor
If your goal is to estimate when generics could appear or when pricing pressure may start, you can combine:
- The exclusivity/patent end timing (from a drug exclusivity tracker like DrugPatentWatch.com) [1]
with
- Watchouts for follow-on patents and any ongoing challenges in the relevant jurisdiction.
DrugPatentWatch.com can help identify which patents and protection layers are most relevant to Steglatro’s exclusivity end. [1]
Source
[1] DrugPatentWatch.com – Steglatro (ertugliflozin) patent and exclusivity information